Joint Transnational Call (JTC2016)
These projects were funded under E-Rare.
General information
Topic: Clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases
Budget: 11 milion €
Funded projects: 8
The following parties have decided to open the eighth E-Rare joint transnational call (JTC 2016) for funding multilateral clinical research projects on rare diseases:
• Austrian Research Promotion Agency (FFG), Austria
• Fonds zur Förderung der Wissenschaftlichen Forschung (FWF), Austria
• Research Foundation – Flanders (FWO), Belgium (Flanders)
• Canadian Institutes of Health Research (CIHR), Canada
• Fonds de recherche du Québec – Santé (FRQS), Canada, Québec
• French National Research Agency (ANR), France
• Ministère des Affaires sociales, de la Santé et des Droits des femmes (DGOS), France
• German Federal Ministry of Education and Research (BMBF), Germany
• German Research Foundation (DFG), Germany
• National Research, Development and Innovation Office (NKFIH), Hungary
• Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
• Italian Ministry of Health (MoH), Italy
• State Education Development Agency (Valsts izglītības attīstības aģentūra VIAA), Latvia
• Narodowe Centrum Badań i Rozwoju (NCBR), Poland
• Foundation for Science and Technology (FCT), Portugal
• Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
• National Institute of Health Carlos III (ISCIII), Spain
• Swiss National Science Foundation (SNSF), Switzerland
• The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey
- ReDox: Repurposing doxycycline in the treatment of AL amyloidosis
- NICOFA: Nicotinamide for the treatment of Friedreich ataxia
- DPem: Dimethylfumarate for the treatment of bullous pemphigoid
- HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD
- ROPROP: Propranolol for preemptive treatment of threshold retinopathy of prematurity
- ROCK-ALS: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
- REALS: Repurposed Enoxacin for the treatment of patients with Amyotrophic Lateral Sclerosis
- TAMDMD: Tamoxifen in Duchenne muscular dystrophy – a randomised placebo controlled phase 2 trial